A new AI tool, BIOPREVENT, predicts serious post-transplant complications months before symptoms appear using blood biomarkers and clinical data.
Key Details
- 1BIOPREVENT was developed by MUSC Hollings Cancer Center and validated with data from 1,310 transplant recipients.
- 2The tool outperformed standard clinical models in predicting chronic graft-versus-host disease (GVHD) and transplant-related death.
- 3BIOPREVENT uses seven immune protein biomarkers and nine clinical factors to assess risk.
- 4Predictions were validated in an independent patient cohort, showing reliable risk stratification up to 18 months post-transplant.
- 5A free, web-based application is available for clinicians to use the tool for research and risk assessment.
Why It Matters
Early identification of high-risk transplant patients can enable closer monitoring and potential intervention before severe complications arise, representing a significant advance in personalized medicine using AI and biomarker data. This AI tool sets a precedent for broader use of machine learning models to improve outcomes in complex medical scenarios requiring longitudinal risk prediction.
Source
EurekAlert
Related News
•EurekAlert
AI and Ground-Penetrating Radar Innovate Detection of Hidden Steel Damage
University of Houston researchers developed an AI and radar-based method to detect hidden damage in cold-formed steel used in building structures.
•EurekAlert
NIH-Funded 'Merlin' Foundation Model Outperforms Specialists in CT AI Tasks
Stanford researchers unveil Merlin, a foundation AI model that outshines specialist models in analyzing 3D CT scans for diagnostics and disease prediction.
•EurekAlert
AI-powered Liquid Biopsy Detects Early Liver Fibrosis and Chronic Disease
AI-based cfDNA fragmentome liquid biopsy can detect early liver fibrosis, cirrhosis, and indicate broader chronic disease signals.